BRCA1 and neoplasm: Several studies have highlighted that BRCA1/2 mutated OC harbor a higher number of tumor specific neo-antigenes and demonstrate increased expression of the immune checkpoint modulators, PD-1 and PD-L1, which indicated that BRCA1/2 mutated OC may be more sensitive to PD-1/PD-L1 inhibitors (25).